EQUASENS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 61.6 EUR | -1.75% |
|
-1.75% | +0.82% |
| May. 08 | Equasens: sales down 5% in Q1 | CF |
| Apr. 30 | Equasens Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2023 | 220M 238M | Sales 2024 * | 226M 245M | Capitalization | 926M 1B |
|---|---|---|---|---|---|
| Net income 2023 | 47M 50.97M | Net income 2024 * | 47M 50.97M | EV / Sales 2023 | 4.18 x |
| Net cash position 2023 * | 35.92M 38.96M | Net cash position 2024 * | 62.63M 67.93M | EV / Sales 2024 * | 3.83 x |
| P/E ratio 2023 |
19.5
x | P/E ratio 2024 * |
19.2
x | Employees | - |
| Yield 2023 * |
1.97% | Yield 2024 * |
2.17% | Free-Float | 32.42% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | -1.75% | ||
| 1 week | -1.75% | ||
| 1 month | +4.58% | ||
| 3 months | +30.92% | ||
| 6 months | +6.57% | ||
| Current year | +0.82% |
1 week
60.50
65.40
1 month
54.1065.40
Current year
46.1565.40
1 year
46.1585.80
3 years
46.15103.00
5 years
41.25124.20
10 years
17.43124.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 90-12-31 | |
Thierry Chapusot
FOU | Founder | 65 | 96-01-24 |
| Director of Finance/CFO | - | 22-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Thierry Chapusot
FOU | Founder | 65 | 96-01-24 |
| Director/Board Member | 46 | 17-06-26 | |
| Director/Board Member | 59 | 99-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 61.6 | -1.75% | 11,875 |
| 24-05-30 | 62.7 | -3.09% | 18,276 |
| 24-05-29 | 64.7 | -0.31% | 6,402 |
| 24-05-28 | 64.9 | +0.15% | 7,298 |
| 24-05-27 | 64.8 | +3.35% | 8,191 |
Real-time Euronext Paris, May 31, 2024 at 11:35 am EDT
More quotes
Equasens is No. 1 in France for publishing and integrating software programs for pharmacies, hospitals, healthcare facilities, laboratories, retirement homes and healthcare professionals. Net sales break down by activity as follows:
- pharmacy software publishing and integration (74%): software programs for managing data bases, information, inventories, orders, electronic care records, etc.;
- publishing of IT solutions for health and medical/social establishments (14.2%): publishing and integration of software packages for retirement homes, hospitals and care homes (software for managing admissions, billing, receipt and accounting management, care management, supply management, etc.);
- development of solutions and infrastructures for e-Health (11.8%): digital communication, telemedicine and telehealth solutions. The group also offers financing solutions for leased goods (Nanceo).
Net sales are distributed geographically as follows: France (89.7%), Italy (5.4%), Belgium (2.9%), Germany (1%), the United Kingdom (0.8%) and Ireland (0.2%).
Sector
IT Services & Consulting
Calendar
2024-06-27
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
61.6
EUR
Average target price
70.07
EUR
Spread / Average Target
+13.74%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +0.82% | 1B | |
| -19.53% | 177B | |
| -3.23% | 159B | |
| +2.05% | 153B | |
| +5.13% | 100B | |
| +9.84% | 81.1B | |
| +22.85% | 75.87B | |
| -8.81% | 69.81B | |
| -31.57% | 45.59B | |
| -9.69% | 42.96B |
- Stock Market
- Equities
- EQS Stock
